Oxycodegol
| Names | |
|---|---|
| IUPAC name
(4R,4aS,7S,7aR,12bS)-9-methoxy-7-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]-3-methyl-1,2,4,5,6,7,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-ol | |
| Other names
Loxicodegol; NKTR-181 | |
| Identifiers | |
3D model (JSmol) |
|
| ChemSpider | |
| DrugBank | |
| KEGG | |
PubChem CID |
|
| UNII | |
| |
| |
| Properties | |
| C31H49NO10 | |
| Molar mass | 595.730 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
Oxycodegol (also known as loxicodegol and NKTR-181) is an experimental μ-opioid receptor agonist for the treatment of pain. It has had success for back pain as an alternative to traditional opioids, which have potential for abuse. It acts more slowly on the central nervous system, reducing risk for abuse and respiratory depression.